Physician profile
William Wagner
NPI 1871567941
$1,028.84
in general payments reported to CMS, 2019-2025
20 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.87 · 2022: $158 · 2023: $278 · 2024: $272 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $238.99 | 2022-2025 | Ubrelvy, Viberzi, Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $115.02 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $108.33 | 2023-2025 | Lokelma, Farxiga |
| Pfizer INC. | $87.07 | 2023-2025 | |
| Sanofi Pasteur INC. | $84.79 | 2022 | |
| Astellas Pharma US INC | $55.12 | 2019-2024 | Veozah |
| Corcept Therapeutics | $41.02 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $40.00 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $36.25 | 2023 | Yupelri |
| Allergan, INC. | $29.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.70 | 2019-2023 | Spiriva Respimat |
| Axsome Therapeutics, INC. | $22.96 | 2024 | Auvelity |
| Lundbeck LLC | $22.34 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $22.17 | 2025 | Injectafer |
| Exact Sciences Corporation | $19.21 | 2025 | The Cologuard Plus Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.94 | 2023 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.16 | 2019 | |
| Amgen INC. | $15.85 | 2024 | Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $14.06 | 2025 | Ajovy |
| Phathom Pharmaceuticals, INC. | $12.62 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.